| 產品名稱 |
HL-60/MX2 |
| 商品貨號 |
B164618 |
| Organism |
Homo sapiens, human |
| Tissue |
peripheral blood |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
acute promyelocytic leukemia |
| Age |
36 years |
| Gender |
female |
| Ethnicity |
Caucasian |
| Storage Conditions |
liquid nitrogen vapor phase |
| Karyotype |
The cells exhibit a reciprocal translocation [rcpt(1;3)-(q21;p23)] not found in the parental cell line. |
| Derivation |
HL-60/MX2 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia.
HL-60/MX1 (see ATCC CRL-2258) cells were selected and subcloned in 1987 for resistance to 39 nM mitoxantrone, an anthracenedione antitumor agent.
Subsequent exposure of the HL-60/MX1 cells to higher concentrations of mitoxantrone led to the emergence of cells capable of growth at a concentration of 190 nM.
These cells were cloned by limiting dilution in soft agar, propagated and tested for sensitively to mitoxantrone. |
| Clinical Data |
36 years
Caucasian
female
|
| Comments |
The clone designated HL-60/MX2 was approximately 35 fold less sensitive to mitoxantrone than the HL-60 parental cells.
HL-60/MX2 cells display atypical multidrug resistance (MDR) with the absence of P-glycoprotein overexpression and altered topoisomerase II catalytic activity and reduced levels of topoisomerase II alpha and beta proteins.
HL-60/MX2 cells are cross-resistant to etoposide, teniposide, bisantrene, dactinomycin, 4'-(9-acridinylamino)methane- sulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids vincristine and vinblastine, melphalan, mitomycin C and cisplatin.
The HL-60/MX2 cells display slight collateral sensitivity to bleomycin.
Resistance to mitoxantrone is stable for up to six months.
|
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 - 2 x 105 viable cells/mL. Maintain cultures at a cell concentration between 2 x 105 and 1.5 x 106 cells/mL. Never allow the cell concentration to exceed 2 x 106 cells/mL.
Interval: Maintain cell density between 1 x 105 and 1.5 x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 13,14 D13S317: 8,11 D16S539: 11 D5S818: 12 D7S820: 11,12 THO1: 7,8 TPOX: 8,11 vWA: 16 |
| Population Doubling Time |
30 hrs |
| Name of Depositor |
WG Harker |
| Deposited As |
Homo sapiens |
| References |
Harker WG, et al. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49: 4542-4549, 1989. PubMed: 2568172
Harker WG, et al. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30: 9953-9961, 1991. PubMed: 1655025
|
